Baxalta Declares Quarterly Dividend

BANNOCKBURN, Ill.--(BUSINESS WIRE)-- The Board of Directors of Baxalta Incorporated (NYSE: BXLT) today declared a quarterly cash dividend of $0.07 per share of common stock. The quarterly dividend will be paid on January 4, 2016, to stockholders of record as of the close of business on December 4, 2015.

“This dividend reflects our continued confidence in the strength and sustainability of our cash flow generation, growth prospects and future performance of the company,” said Robert Hombach, chief financial officer and chief operations officer, Baxalta. “Baxalta remains committed to returning enhanced value to shareholders while balancing investments in innovation, business development initiatives and other growth opportunities.”

About Baxalta

Baxalta Incorporated (NYSE: BXLT) is a $6 billion global biopharmaceutical leader developing, manufacturing and commercializing therapies for orphan diseases and underserved conditions in hematology, oncology and immunology. Driven by passion to make a meaningful impact on patients’ lives, Baxalta’s broad and diverse pipeline includes biologics with novel mechanisms and advanced technology platforms such as gene therapy. The Baxalta Global Innovation and R&D Center is located in Cambridge, Massachusetts. Launched in 2015 following separation from Baxter International Inc., Baxalta’s heritage in biopharmaceuticals spans decades. Baxalta’s therapies are available in more than 100 countries and it has advanced biological manufacturing operations across 12 facilities, including state-of-the-art recombinant production and plasma fractionation. Headquartered in Northern Illinois, Baxalta employs 16,000 employees worldwide.

Forward-Looking Statements

This release includes forward-looking statements concerning Baxalta’s dividend. Such statements are made of the date that they were first issued and are based on current expectations, beliefs and assumptions of management. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond Baxalta's control and which could cause actual results to differ materially from those in the forward-looking statements, including the following: continued strength in the company’s financial position, including cash flows; future decisions of the board of directors of the company with respect to the payment of dividends relative to alternative uses of funds; and other risks identified in Baxalta’s registration statement on Form 10 and other Securities and Exchange Commission filings, all of which are available on Baxalta’s website. Baxalta expressly disclaims any intent or obligation to update these forward-looking statements except as required by law.

View source version on businesswire.com: http://www.businesswire.com/news/home/20151117006983/en/

Baxalta Media Relations
Geoffrey Mogilner, +1-224-940-8619
[email protected]
or
Baxalta Investor Relations
Mary Kay Ladone, +1-224-948-3371
[email protected]
or
Lorna Williams, +1-224-948-3511
[email protected]

Source: Baxalta Incorporated

You May Also Be Interested In

• WANPY® Becomes the First Chinese Pet Food Brand to Receive the WPA International Excellence Award, Earning International Recognition for Its Systematic Capabilities
• More Cancer Patients Are Opting to Preserve Their Tumors
• Quanta Computer and Quantinuum Partner to Build an Industrial Foundation for Large-Scale Quantum Computing